ANX-042 Healthy Volunteer Dose Escalation Study

The purpose of this study was to investigate the safety and tolerability of ANX-042 when administered by continuous intravenous (IV) infusion in healthy volunteers.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: ANX-042; Drug: Placebo

Detailed Description

Each participant received a total of two, approximately 12-hour continuous infusions of ANX-042 and one 12-hour continuous infusion of placebo, with a 36-hour washout period between treatments.

This study was conducted by Anexon, Inc. at Celerion, in Lincoln, Nebraska.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Nebraska
    • Lincoln, Nebraska, United States, 68502
      • Celerion

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Men or women of non-reproductive potential (WNRP)

  • Men must be willing to use effective contraception and not donate sperm for up to 90 days after the final dose of study drug
  • Women must be of non-reproductive potential defined as a history of surgical sterilization or postmenopausal status (that is, greater than ( >) 50 years of age with >12 months amenorrhea while not using hormonal contraceptives or >50 years of age with 6-12 months of amenorrhea and follicle stimulating hormone (FSH) level >40 international unit/liter (IU/L)
• Good health status, physically active without cardio-respiratory limitations and minimal concomitant medications as determined by medical history and physical examination
• Able and willing to comply with study procedures, including controlled sodium (Na) intake and restriction of caffeine and tobacco product
• Have given written informed consent prior to the initiation of any study procedures

Exclusion Criteria:

• History of cardiovascular disease, unexplained syncope, postural tachycardia syndrome or frequent postural hypotension
• History or current evidence of respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders that would constitute a risk when taking the study medication or interfere with the interpretation of data
• Clinically significantly abnormal clinical laboratory results (including Hepatitis B, Hepatitis C and Human Immunodeficiency Virus (HIV) serology) or physical examination results (confirmed by repeat measurement, if appropriate) that, in the opinion of the Investigator, would constitute a risk when taking the study medication or interfere with the interpretation of data

• Abnormal orthostatic Blood Pressure/Heart Rate (BP/HR) response at screening as defined by:

  • Systolic Blood Pressure (BP) decrease >20 millimeters of mercury (mmHg)
  • Diastolic BP decrease >10 mmHg, or
  • HR increase >25 beats per minute (bpm) and to a level above 100 bpm
• One or two supine values must be obtained between 8 and 10 minutes of supine rest. One or two upright values must be obtained between 3 and 5 minutes upright with the arm passively supported to maintain the brachial artery at heart level
• Abnormal 12-lead electrocardiogram (ECG) that interferes with proper measurement of QT-interval or, in the opinion of the Investigator, increases the risk of participating in the study
• Elevated BP (>140/90 mmHg) in any posture, confirmed by repeat measurement
• Current use (within 7 days of first dosing) or expected need for concomitant medications with hemodynamic effects including: non-steroidal anti-inflammatory drugs (NSAIDS), decongestants, BP medications, diuretics, monoamine oxidase inhibitors, norepinephrine uptake inhibitors (for example, attention-deficit disorder medications, anti-depressants) and erectile dysfunction medications. Medications with low likelihood of hemodynamic or renal effects are permitted (for example, acetaminophen, vitamins, stable thyroid hormone, gastritis therapies, antihistamines, topical medications, et cetera) after approval by the Investigator
• Evidence of current or recent use of known drugs of abuse and/or positive findings on urinary drug screening
• History of an average weekly alcohol intake that exceeds 21 units per week (1 unit equal to (=) 12 ounces (oz) or 360 milliliters (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits), or are unwilling to stop alcohol consumption for the duration of the study
• History of regular smoking of >5 cigarettes, cigars and/or pipe bowls of tobacco per day
• Known allergies to nesiritide (Natrecor)
• History of blood donation of >500 mL within one month, or plasma donation within 14 days, of first dosing
• Are currently enrolled in, or have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
• Are investigator site personnel directly affiliated with this study or their immediate family members. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted
• Are Lilly or Anexon employees or employees of any third-party organization (TPO) involved with the study that require exclusion of their employees

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ANX-042: 0.001 mcg/kg/min (with low sodium diet); 0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Experimental: ANX-042: 0.001 mcg/kg/min; 0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Experimental: ANX-042: 0.003 mcg/kg/min (low sodium diet); 0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Experimental: ANX-042: 0.003 mcg/kg/min; 0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Experimental: ANX-042: 0.0065 mcg/kg/min (low sodium diet); 0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Experimental: ANX-042: 0.01 mcg/kg/min (low sodium diet); 0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Experimental: ANX-042: 0.01 mcg/kg/min; 0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Experimental: ANX-042: 0.03 mcg/kg/min; 0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Experimental: ANX-042: 0.1 mcg/kg/min; 0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Experimental: ANX-042: 0.3 mcg/kg/min; 0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake	Drug: ANX-042; Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Placebo Comparator: Placebo (low sodium diet); Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake	Drug: Placebo; Administered once by 12 hour continuous intravenous infusion with D5W (USP)
Placebo Comparator: Placebo; Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake	Drug: Placebo; Administered once by 12 hour continuous intravenous infusion with D5W (USP)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of participants with one or more drug-related adverse events (AEs) or any serious AEs	0 to 4 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Pharmacokinetics: Area under the plasma concentration-time curve (AUC) of ANX-042	0 to 24 hours post dose
Pharmacokinetics: Steady state plasma concentration of ANX-042	12 hours post dose

Collaborators and Investigators

• Sponsor: Mayo Clinic
• Collaborators: Celerion; Anexon, Incorporated
• Investigators: Study Director: Email: Anexon@Choruspharma.com, Anexon, Incorporated

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2012
• Primary Completion (Actual): December 1, 2012
• Study Completion (Actual): December 1, 2012

Study Registration Dates

• First Submitted: July 9, 2012
• First Submitted That Met QC Criteria: July 10, 2012
• First Posted (Estimate): July 11, 2012

Study Record Updates

• Last Update Posted (Actual): October 13, 2017
• Last Update Submitted That Met QC Criteria: October 11, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Other Study ID Numbers: ANX-042-C100

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No